INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES
Propagating Peptides With Peptilogics' Jonathan Steckbeck, Ph.D.
Peptilogics CEO and founder Dr. Jonathan Steckbeck walks us through his transition from academic work into a clinical-stage company, how he's sustaining the company in a lean capital market, the big demand for antibiotic peptides, and more.
Resilient Biopharma Leadership With Ambrx's Dan O'Connor
We welcome back Dan O'Connor, CEO of Ambrx, to discuss the resurgence of Ambrx and leadership resilience in an industry that demands it on this episode of the Business of Biotech.
Drug Development Strategy Solutions
Navigate the complex challenges experienced during drug development at each stage to ensure a seamless progression and maximize the potential for success in the dynamic landscape of the life sciences industry.
Commercial Strategy Solutions
Obtain essential insights and solutions to pivotal questions that guarantee a successful return on investment for your product.
Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman
Howard Berman, Ph.D. knows well the tragedy of cognitive decline. Now CEO of Coya Therapeutics, Berman joined the Business of Biotech to share his strategy during a stingy stretch in capital markets.
Building An In-House Cell & Gene Manufacturing Facility: Best Practices & Lessons Learned
Listen in on a panel discussion where cell and gene therapy experts share their experiences in building state-of-the-art manufacturing facilities and offering detailed advice on how your company can do the same.
Fixing The Regenerative Medicine Supply Chain
What challenges do outdated cryopreservation techniques raise for companies attempting to shorten the timeline between discovery and clinical implementation and meet the growing demand for CGT therapies.
Product Expertise & Market Knowledge Secures Fast-Track Review
Learn about the importance of combining product expertise with target market knowledge to create a winning strategy.
Key Considerations For Successful Launch Of Cell & Gene Therapies
Cell and gene therapies face steeper challenges at launch than traditional drugs do, potentially limiting their adoption and thus their potential to transform patients’ lives. This article examines key considerations for strategic market access and launch excellence.
Delivering On Our Promise To Patients: Why Funding Challenges, Risk Sensitivity Stymie The CGT Space
There appears to be investment money available, and there is certainly no shortage of CGT companies seeking early investment. Yet, rarely the two shall meet. What exactly is going on?